Stuart Silverman, MD


Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MD

As the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]

Davangere P. Devanand, MBBS, MD


Davangere Devanand, MBBS, MD: Lithium for Agitation in Alzheimer Disease

The professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.

Jan Hedner, MD, PhD


Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep Apnea

Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.

Jan Hillert, MD, PhD


Jan Hillert, MD, PhD: Stem Cell Transplants in MS

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.

Danny Eckert, PhD


Danny Eckert, PhD: Pharmacotherapies Reducing OSA Severity

Proof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.

Imad Michel Najm, MD


Serial Assessments Used in Groundbreaking Brain Study: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided perspective on the in-depth testing neurologically healthy patients in the Brain Study will undergo. [WATCH TIME: 3 minutes]

Michael K. Racke, MD


Alzheimer Disease: Separating Fact from Fiction

In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.

Anup Patel, MD


Groundbreaking Epilepsy Research Studies on the Horizon in 2023: Anup Patel, MD

The pediatric neurologist at Nationwide Children's Hospital discussed the epilepsy research studies that he is excited about in 2023. [WATCH TIME: 4 minutes]

Jeffrey Buchhalter, MD


Jeffrey Buchhalter, MD: Disclosing SUDEP Risk to Patients With Epilepsy

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.

Jessica Robinson-Papp, MD


Jessica Robinson-Papp, MD: Medical Marijuana for Neurologic Conditions

The professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.

Amy B. Sullivan, PsyD


Amy B. Sullivan, PsyD: Screening MS Patients for Comorbidities

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.

Peter J. Goadsby, MD, PhD, DSc


Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Kathryn A. Davis, MD, FAES


Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MSc

The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Anthony Traboulsee, MD, FRCPC


CMSC Live: 2024 Annual Meeting Day 1

Host Jeffrey Wilken, PhD, chats with Robert Naismith, MD; Jiwon Oh, MD, PhD; and Anthony Traboulsee, MD, about the first day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

John L. Berk, MD


Future Treatment of hATTR Amyloidosis

Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.

Lutz Frolich, MD, PhD


Lutz Frolich, MD, PhD: Learning from Negative Trials

Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.

James A. Charles, MD, FAAN, FAHS


Justifying Use of CGRP mAbs in Pediatric Patients With Migraine

What happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?

Jacqueline French, MD


Jacqueline French, MD: Barriers to Identifying Nonmotor Seizures

The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the need to improve education about nonmotor seizures.

Amit Rakhit, MD, MBA


Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare Conditions

The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.

Andre Machado, MD, PhD


Andre Machado, MD, PhD: Multidisciplinary Treatment in Movement Disorders

The Chairman of the Neurological Institute at Cleveland Clinic provided insight into the multidisciplinary decision-making process for patients with movement disorders at the center.

Trevor J. Resnick, MD


Therapies for Children and Adults with Dravet Syndrome

The panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.  

Matthew B. Harms, MD


Highlighting Genetic Discoveries and Therapeutic Developments in ALS: Matthew B. Harms, MD

The associate professor of neurology at Columbia University talked about a track session that he will be chairing at the upcoming MDA conference on amyotrophic lateral sclerosis genetic research. [WATCH TIME: 5 minutes]

Ronald Witteles, MD


Future Treatment of hATTR Amyloidosis

Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.

Eric Segal, MD


2020 Epilepsy Review: Much to Be Excited About

Despite 2020 being a challenging year for those in medicine, the epilepsy therapeutic space featured a number of key steps forward.

Hideki Garren, MD, PhD


Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight Open

The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.

© 2024 MJH Life Sciences

All rights reserved.